InnoCan Pharma Overview
Get informed when a big investor buys or sells
+ Follow-6.54
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, INNPF shows a P/E ratio of -6.54. That is below the sector sector average of 27.12. Scroll down for historical charts and peer comparison views.
The its sector sector average P/E ratio is about 27.12. InnoCan Pharma is at -6.54, which is lower that average. That is roughly 124.1% below the sector mean. Use the comparison chart on this page to see how INNPF stacks up against individual peers as well.
Investors watch INNPF's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. InnoCan Pharma's latest reading is -6.54. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has InnoCan Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -6.54) with ownership activity and broader fundamentals.
